Concepedia

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Karen A. Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth D. Swenerton, André Robidoux, Katia Tonkin, Hal W. Hirte, David G. Huntsman, Mark Clemons, C. Blake Gilks,

The Lancet Oncology · 2011 · 1.1K citations · 21 references

References

21

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.2K citations

Life Sciences, Cancer Biology, Oncology +12

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text

Medicine, Oncology, Pathology +11

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Medicine, Oncology, Pharmacology +17